Comparison of Buspirone and Ritaline in the treatment of ADHD
Phase 2
Completed
- Conditions
- Disturbance of activity and attention.Disturbance of activity and attention
- Registration Number
- IRCT201011101556N17
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Inclusion Criteria: Diagnosis of ADHD based on DSMIV age between 6-17
Exclusion Criteria
receiving of any psychotropics drugs during past two weeks, , serum creatinin >2, hepatic failure, presence of seizures, development of extrapyramidal signs, development of serotonin syndrome
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of ADHD. Timepoint: Week 0 (before treatment) and Weeks 3 and 6 after treatment. Method of measurement: Teacher and Parent ADHD Rating Scale.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Buspirone's efficacy compared to Ritaline in ADHD treatment in IRCT201011101556N17 Phase II trial?
How does Buspirone's effectiveness in Phase II IRCT201011101556N17 trial compare to standard-of-care stimulants for ADHD subtypes?
Which biomarkers correlate with treatment response in the IRCT201011101556N17 Phase II study comparing Buspirone and Ritaline for ADHD?
What adverse events are reported in the IRCT201011101556N17 Phase II trial of Buspirone versus Ritaline for ADHD, and how are they managed?
Are there non-stimulant ADHD therapies or combination strategies with Buspirone that rival Ritaline's efficacy in IRCT201011101556N17 Phase II research?